We can’t show the full text here under this license. Use the link below to read it at the source.
Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study
Tirzepatide’s effectiveness in patients with heart failure and preserved pumping function
AI simplified
Abstract
Tirzepatide use was associated with a 52% lower risk of heart failure exacerbation and all-cause mortality in patients with heart failure with preserved ejection fraction.
- In a cohort of 14,154 patients with heart failure with preserved ejection fraction, tirzepatide was linked to improved outcomes.
- The primary composite outcome showed a hazard ratio of 0.52 for heart failure exacerbation and all-cause mortality.
- Significantly lower risks were also observed for major adverse cardiovascular events ( 0.64) and major adverse kidney events (HR 0.44).
- Subgroup analyses indicated consistent benefits across different patient groups.
- Sensitivity analyses validated the reliability of these findings.
AI simplified
Key numbers
0.52
Decrease in Risk
for heart failure exacerbation and all-cause mortality.
0.64
Decrease in Major Adverse Cardiovascular Events Risk
for major adverse cardiovascular events.
0.44
Decrease in Major Adverse Kidney Events Risk
for major adverse kidney events.